GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pyxis Oncology Inc (NAS:PYXS) » Definitions » Cash Flow from Investing

Pyxis Oncology (Pyxis Oncology) Cash Flow from Investing : $-104.85 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Pyxis Oncology Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Pyxis Oncology spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $10.23 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $20.46 Mil from other investing activities. In all, Pyxis Oncology gained $10.23 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Pyxis Oncology Cash Flow from Investing Historical Data

The historical data trend for Pyxis Oncology's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pyxis Oncology Cash Flow from Investing Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
- -1.48 -0.59 -6.40 -104.85

Pyxis Oncology Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.86 -99.39 -22.26 6.57 10.23

Pyxis Oncology Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Pyxis Oncology's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Pyxis Oncology's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-104.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pyxis Oncology  (NAS:PYXS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Pyxis Oncology's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Pyxis Oncology's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Pyxis Oncology's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Pyxis Oncology's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Pyxis Oncology's purchase of investment for the three months ended in Dec. 2023 was $-10.23 Mil. It means Pyxis Oncology spent {stock_data.stock.currency_symbol}}10.23 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Pyxis Oncology's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Pyxis Oncology's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Pyxis Oncology paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Pyxis Oncology's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Pyxis Oncology paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Pyxis Oncology's cash from other investing activities for the three months ended in Dec. 2023 was $20.46 Mil. It means Pyxis Oncology received $20.46 Mil from other investing activities.


Pyxis Oncology Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Pyxis Oncology's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Pyxis Oncology (Pyxis Oncology) Business Description

Traded in Other Exchanges
N/A
Address
150 Cambridgepark Drive, Cambridge, MA, USA, 02140
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Its lead ADC product candidate is PYX-201, an investigational human IgG1 isotype site-specifically conjugated with an auristatin toxin targeting EDB that initially develop for solid tumors, including NSCLC, hormone receptor-positive breast, ovarian and thyroid cancer. The IO product candidate is PYX-106, designed to block Siglec-15-mediated suppression of T-cell proliferation and function.
Executives
Pamela Ann Connealy officer: Chief Financial Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jitendra Wadhane officer: Chief Accounting Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Lara Sullivan director, officer: Chief Executive Officer C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD, SUITE 455, ROCKVILLE MD 20850
Jakob Dupont director C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Pfizer Inc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Pfizer Ventures (us) Llc 10 percent owner 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192
Rachel Humphrey director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
Mark Chin other: Former Director 20 BERKELEY SQUARE, MAYFAIR, LONDON X0 W1J 6EQ
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Thomas Civik director C/O FOUNDATION MEDICINE, INC., 150 SECOND STREET, CAMBRIDGE MA 02141
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Freda C Lewis-hall director C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Ronald Herbst officer: Chief Scientific Officer 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140